Observational Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 6, 2022; 10(10): 3101-3112
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3101
Oxaliplatin-induced neuropathy and colo-rectal cancer patient’s quality of life: Practical lessons from a prospective cross-sectional, real-world study
Iulian Prutianu, Teodora Alexa-Stratulat, Elena Octaviana Cristea, Andrei Nicolau, Diana Cornelia Moisuc, Alina Alexandra Covrig, Karina Ivanov, Adina Emilia Croitoru, Monica Ionela Miron, Mihaela Ioana Dinu, Anca Viorica Ivanov, Mihai Vasile Marinca, Iulian Radu, Bogdan Gafton
Iulian Prutianu, Medical Oncology, SC MNT Healthcare Europe SRL, Iasi 700021, Romania
Teodora Alexa-Stratulat, Mihai Vasile Marinca, Bogdan Gafton, Medical Oncology-Radiotherapy, University of Medicine and Pharmacy Grigore T Popa Iasi, Iasi 700483, Romania
Elena Octaviana Cristea, Diana Cornelia Moisuc, Alina Alexandra Covrig, Karina Ivanov, Medical Oncology, Regional Oncology Institute Iasi, Iasi 700483, Romania
Andrei Nicolau, Oral and Maxillo-facial Surgery, University of Medicine and Pharmacy Grigore T Popa Iasi, Iasi 700021, Romania
Adina Emilia Croitoru, Monica Ionela Miron, Mihaela Ioana Dinu, Department of Medical Oncology, Fundeni Clinical Institute, Bucuresti 022328, Romania
Anca Viorica Ivanov, Paediatrics, University of Medicine and Pharmacy “Grigore T Popa”, Iasi 700021, Romania
Iulian Radu, Department of Surgery, Department of Surgical Oncology, University of Medicine and Pharmacy “Grigore T Popa”, Regional Institute of Oncology, Iasi 700021, Romania
Author contributions: Prutianu I, Marinca MV, Gafton B designed the research study; Prutianu I, Alexa-Stratulat T, Cristea EO, Nicolau A, Moisuc DC, Covrig AA, Ivanov K, Croitoru AE, Miron MI, Dinu MI, Ivanv AV, Marinca MV, Radu I performed the research; Prutianu I, Alexa-Stratulat T, Cristea EO, Moisuc DC, Ivanv AV, Gafton B analyzed the data and wrote the manuscript; all authors have contributed significantly to manuscript editing and all authors proofread and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Regional Institute of Oncology Iași Institutional Review Board.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: Dataset available from the corresponding author at teodora.alexa-stratulat@umfiasi.ro. Even though consent was not obtained for data sharing, the presented data are anonymized and risk of identification is low.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Teodora Alexa-Stratulat, MD, PhD, Assistant Professor, Medical Oncology-Radiotherapy, University of Medicine and Pharmacy Grigore T Popa Iasi, Independentei Street No. 16, Iasi 700483, Romania. teodora.alexa-stratulat@umfiasi.ro
Received: May 15, 2021
Peer-review started: May 15, 2021
First decision: June 12, 2021
Revised: July 27, 2021
Accepted: February 22, 2022
Article in press: February 22, 2022
Published online: April 6, 2022
Core Tip

Core Tip: Oxaliplatin-induced neuropathy (OIN) is a serious acute and chronic complication of colorectal cancer chemotherapy. This study aims to offer a real-world perspective on the incidence of acute OIN during chemotherapy and its impact on the quality of life. We found that more than 50% of colon cancer patients discontinue chemotherapy, and the main reason is neuropathy. Also, individuals with neuropathy have a lower quality of life, independent of other factors. All in all, as the number of cancer survivors increases, guidelines should be reviewed in order to minimize the risk of chronic OIN as much as possible.